Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-10-22
2011-12-13
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C424S161100
Reexamination Certificate
active
08076085
ABSTRACT:
The present inventors have discovered that the presence of antibodies reactive with residues 94-117 of the PreS1 component of the hepatitis B surface antigen (HBsAg) in an individual with HBV infection correlates closely with the effectiveness of interferon (IFN) in treating the individual. Methods and means based on this finding are provided herein.
REFERENCES:
patent: 4847080 (1989-07-01), Neurath et al.
patent: 5204096 (1993-04-01), Neurath et al.
patent: 154902 (1985-09-01), None
patent: 0 250 253 (1987-12-01), None
patent: 448126 (1991-09-01), None
patent: 0 491 077 (1992-06-01), None
patent: 94/04922 (1994-03-01), None
Paul, Fundamental Immunology, 5thEdition, 2003, pp. 718-720.
Wei et al. Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay, World J. Gastroenterol., 2002, 8(2):276-281.
Zavaglia et al., Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up, Italian Journal of Gastroenterology, Jul.-Aug. 1996 , 28 (6):324-331. Abstract.
Wei et al., Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay, World J Gastroenterol, 2002, 8(2):276-281.
International Search Report for PCT/EP04/11958 dated Sep. 6, 2005.
Alberti et al.,Fine specificity of human antibody response to the PreS1 domain of hepatitis B virus, Hepatology, vol. 12, No. 2, Aug. 1990, pp. 199-203, XP009052827.
Petit et al.,PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B, J. Hepatol., vol. 20, No. 1, Jan. 1994, pp. 47-56, XP009052825.
Lai et al, “Viral hepatitis B”, The Lancet 362:2089-2094 (2003).
Heathcote, E. Jenny, “Demography and Presentation of Chronic Hepatitis B Virus Infection”, The American Journal of Medicine 121:S3-S11 (2008).
De Franchis et al, “EASL International Consensus Conference on Hepatitis B”, Journal of Hepatology 39:S3-S25 (2003).
Chu, Chia-Ming, “Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma”, Journal of Gastroenterology and Hepatology 15(Suppl S2):E25-E30 (2000).
Fattovich et al, “Long-Term Outcome of Hepatitis BeAntigen-Positive Patients with Compensated Cirrhosis Treated With Interferon Alfa”, Hepatology 26:1338-1342 (1997).
Ikeda et al, “Interferon Decreases Hepatocellular Carcinogenesis in Patients with Cirrhosis Caused by the Hepatitis B Virus”, Cancer 82(5):827-835 (1998).
Liaw and Chu, “Hepatitis B virus infection”, The Lanced 373:S82-S92 (2009).
Liaw, Yun-Fan, “Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy”, Antivirus Therapy 11:669-679 (2006).
Cooksley, Graham, “The treatment of hepatitis Beantigen-positive chronic hepatitis B with pegylated interferon”, Journal of Hepatology 39:S143-S145 (2003).
Craxi et al, “Interferon-α for HBeAg-positive chronic hepatitis B”, Journal of Hepatology 39:S99-S105 (2003).
Wong et al, “Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B”, Ann. Intern. Med. 119:312-323 (1993).
Hellstrom Ulla
Sylvan Staffan
HBV Theranostica AB
Kinsey White Nicole
Lucas Zachariah
Nixon & Vanderhye P.C.
LandOfFree
Methods and means relating to hepatitis B infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and means relating to hepatitis B infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and means relating to hepatitis B infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294026